| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62d56c0dac86d852b317072fd1d292d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc4994b001c65e1566670b1cc698a88c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_621701b56a94878d34afd92f07ba915d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72e0c421f613fe69d5c30f1e87951fa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0a2c1c522e86978801df08c05201e6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51fb995196a6585b7fe473fbb01658f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1a08ec7d8278076832e6989a4377d3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa367b19938a6f43087e8702b9e49106 |
| publicationDate |
2020-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202011941-A |
| titleOfInvention |
Inhalable sustained-release composition for treating lung diseases |
| abstract |
Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety. |
| priorityDate |
2018-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |